WO2000009071A3 - Nouvelle preparation a base de liposomes utilisable dans la traitement du cancer et d'autres maladies proliferantes - Google Patents

Nouvelle preparation a base de liposomes utilisable dans la traitement du cancer et d'autres maladies proliferantes Download PDF

Info

Publication number
WO2000009071A3
WO2000009071A3 PCT/IN1999/000037 IN9900037W WO0009071A3 WO 2000009071 A3 WO2000009071 A3 WO 2000009071A3 IN 9900037 W IN9900037 W IN 9900037W WO 0009071 A3 WO0009071 A3 WO 0009071A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cancer
liposomal formulation
formulation useful
proliferation diseases
Prior art date
Application number
PCT/IN1999/000037
Other languages
English (en)
Other versions
WO2000009071A2 (fr
Inventor
Suresh Kumar Gupta
Shiladitya Sengupta
Thirumurthy Velpandian
Original Assignee
All India Inst Med
Suresh Kumar Gupta
Shiladitya Sengupta
Thirumurthy Velpandian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by All India Inst Med, Suresh Kumar Gupta, Shiladitya Sengupta, Thirumurthy Velpandian filed Critical All India Inst Med
Priority to AU16789/00A priority Critical patent/AU1678900A/en
Publication of WO2000009071A2 publication Critical patent/WO2000009071A2/fr
Publication of WO2000009071A3 publication Critical patent/WO2000009071A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une nouvelle préparation à base de liposomes utilisable dans le traitement du cancer et d'autres maladies proliférantes plus stable et plus efficace et peu toxique consistant en un mélange d'au moins une épipodophyllotoxine ou ses analogues ou dérivés, en phospholipides, en stérols, en antioxydants et en cryoprotecteurs. L'invention porte également sur une trousse de liposomes utilisant ladite préparation et sur un procédé de traitement des animaux et des humains à l'aide de ladite préparation.
PCT/IN1999/000037 1998-08-11 1999-08-10 Nouvelle preparation a base de liposomes utilisable dans la traitement du cancer et d'autres maladies proliferantes WO2000009071A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16789/00A AU1678900A (en) 1998-08-11 1999-08-10 A novel liposomal formulation useful in treatment of cancer and other proliferation diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2337/DEL/98 1998-08-11
IN2337DE1998 1998-08-11

Publications (2)

Publication Number Publication Date
WO2000009071A2 WO2000009071A2 (fr) 2000-02-24
WO2000009071A3 true WO2000009071A3 (fr) 2000-06-15

Family

ID=11092773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN1999/000037 WO2000009071A2 (fr) 1998-08-11 1999-08-10 Nouvelle preparation a base de liposomes utilisable dans la traitement du cancer et d'autres maladies proliferantes

Country Status (2)

Country Link
AU (1) AU1678900A (fr)
WO (1) WO2000009071A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393595A1 (fr) * 1999-12-10 2001-06-14 Gigi Chiu Compositions d'excipient a base de lipides ayant des fonctions de reaction au moyen d'une surface protegee
US8883856B2 (en) * 2000-02-28 2014-11-11 John Jackson Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
CN107811971B (zh) 2004-05-03 2021-10-29 益普生生物制药公司 用于药物输送的脂质体
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1871343A2 (fr) 2005-04-12 2008-01-02 Wisconsin Alumni Research Foundation Composition micellaire polymere et medicament contenu dans celle-ci
EP2480207B1 (fr) 2009-09-25 2016-11-09 Wisconsin Alumni Research Foundation Encapsulation d'agents thérapeutiques dans des micelles
RU2732567C2 (ru) 2015-10-16 2020-09-21 Ипсен Биофарм Лтд. Стабилизированные фармацевтические композиции камптотецина
CN111701026B (zh) * 2020-06-28 2022-10-21 吴燕 抗肿瘤的组合药物纳米载体及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438091A2 (fr) * 1990-01-19 1991-07-24 Nippon Kayaku Kabushiki Kaisha Préparation lyophilisée contenant un dérivé 2-diméthylamino d'étoposide
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
WO1997038731A1 (fr) * 1996-04-18 1997-10-23 The Regents Of The University Of California Immunoliposomes optimisant l'internalisation dans des cellules cibles
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438091A2 (fr) * 1990-01-19 1991-07-24 Nippon Kayaku Kabushiki Kaisha Préparation lyophilisée contenant un dérivé 2-diméthylamino d'étoposide
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
WO1997038731A1 (fr) * 1996-04-18 1997-10-23 The Regents Of The University Of California Immunoliposomes optimisant l'internalisation dans des cellules cibles

Also Published As

Publication number Publication date
WO2000009071A2 (fr) 2000-02-24
AU1678900A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
CA2366702A1 (fr) Compositions et procedes d'administration amelioree d'agents therapeutiques hydrophobes ionisables
WO1999038877A3 (fr) Derives de 2-(purine-9-yl)-tetrahydrofurane-3,4-diol
CA2350538A1 (fr) Derives de pyrazolopyrimidinone utiles pour traiter l'impuissance
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
WO2005013907A3 (fr) Derives de pyrrolo[1,2-b]pyridazine
WO2003002136A3 (fr) Formulation stable de glp-1 modifie
GR3035936T3 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2301057A1 (fr) Procede permettant d'administrer un taxane liposomal encapsule
CA2326761A1 (fr) Agents antitumoraux
TW200510385A (en) Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0204431A3 (en) 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use, process for their preparation and pharmaceutical compositions containing them
HUP0402291A2 (hu) Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2005000248A3 (fr) Compositions et procedes de traitement de la peau
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
WO2000009071A3 (fr) Nouvelle preparation a base de liposomes utilisable dans la traitement du cancer et d'autres maladies proliferantes
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU2001228825A1 (en) Remedies
ID27765A (id) Plester gel yang mengandung steroid dan proses pembuatannya
CA2063273A1 (fr) Surfactants pulmonaires et methodes
EP1238587A3 (fr) Compositions biopesticides
WO2002062334A3 (fr) Composes de chimioprevention des cancers et compositions et procedes de traitement des cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16789

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642